REMEDi4ALL launched yesterday with the aim of making a major leap forward in drug repurposing. This promising approach to drug development consisting in the identification, testing, and validation of new therapeutic indications for existing medications, is a developing field but faces numerous barriers and systemic inefficiencies. Still, its potential to significantly bring down times and costs of drug development -it focuses on already approved, discontinued, shelved or investigational therapeutics- makes this novel strategy attractive for rare and neglected conditions, cancer, emerging public health threats such as COVID-19 or new drug combinations. It also translates into more sustainable health systems.

The REMEDI4ALL initiative will:

  • develop an innovation platform supporting promising, high impact drug repurposing projects championed by patients in any phase of development and disease area;
  • establish a global community that contributes to informing and shaping policy and advancing debate and knowledge exchange


EATRIS, the European infrastructure for translational medicine, will lead this multidisciplinary consortium involving 24 European organisations with the common goal of making cost-effective repurposed medicines more widely available.

To advance knowledge in the field of medicine repurposing and address substantial obstacles -fragmented and siloed research; non-standardised datasets; heterogenous quality of computational tools; poor patient engagement or lack of incentives and policies to support and enhance drug repurposing- the European Union (EU) through the Horizon Europe (HE) programme will invest 23 million euros in REMEDi4ALL over the next 5 years. It is expected that, due to REMEDi4ALL, more (and better) repurposed therapeutics will be widely available thanks to more agile, cutting-edge development processes, ultimately contributing to increased sustainability of health systems.


A favourable eco-system for drug repurposing

The project kicks off with the ambition of establishing a European research and innovation eco-system that facilitates fast and cost-effective patient-centric development and access to repurposed medicines. To this end, REMEDi4ALL will:

  • build a state-of-the-art platform to provide expertise and services across the complete value chain (scientific, methodological, financial, legal, regulatory, intellectual property) for patient-centric medicine repurposing at every development stage and in any disease area.
  • assemble advanced in silico tools for Machine Learning (ML) and Artificial Intelligence (AI), open datasets and tools and expertise required to understand the mechanism of action of specific medicines.
  • create a global community of practice connected in a think-tank-like environment through impactful multidisciplinary activities and events.
  • train and educate the next generation of researchers, clinicians, patients, policymakers, regulators and funders in cutting-edge drug repurposing tools and processes.
  • favour dialogue and debate to advance policy and fair access to repurposed medicines across the EU.

REMEDi4ALL has selected four medicine repurposing projects in different stages of development to demonstrate the viability of the newly created platform. Each project covers a different therapeutic area with high unmet medical needs– pancreatic cancer, COVID-19, rare diseases and ultra-rare diseases. These projects will first be onboarded to ensure a patient-centric approach before testing all elements of the platform to optimise its tools and services.


A multidisciplinary effort to cover every aspect of drug repurposing

The REMEDi4ALL consortium brings together a unique combination of expertise to address the complexities of drug repurposing. Under the leadership of EATRIS, the European infrastructure for translational medicine, 24 organisations in the fields of clinical and translational research, clinical operations, patient engagement and education, regulatory framework, funding, governance, Health Technology Assessment (HTA) or pricing and reimbursement will closely collaborate to make drug repurposing mainstream.

It’s an enormous privilege to work with this team of leading international experts, institutions and patient representatives in such an important and high potential area for European health. REMEDI4ALL will truly transform drug repurposing by making the process more transparent, efficient and – most importantly – completely patient-centred” expressed Anton Ussi, CEO at EATRIS ERIC.

The 24 partners participants include:

  • EATRIS (Coordinator) – The Netherlands
  • Fraunhofer-Gesellschaft – Germany
  • Helsingin yliopisto (FIMM-UH) – Finland
  • European Clinical Research Infrastructure Network (ECRIN) – France
  • Istituto Di Ricerche Farmacologiche Mario Negri (IRFMN) – Italy
  • Istituto Nazionale Tumori Fondazione Pascale (INT-NA) – Italy
  • European Organisation For Rare Diseases  (EURORDIS) – France
  • Dompé farmaceutici Spa (DOMPÉ) – Italy
  • ZonMw – The Netherlands
  • Teamit Research – Spain
  • Medicines For Europe (MfEU) – Belgium
  • Syreon Kutato Intezet Korlatolt Felelossegu Tarsasag (SRI) – Hungary
  • Karolinska Institutet (KI) – Sweden
  • Chemotargets – Spain
  • Anticancer Fund (ACF) – Belgium
  • Univerza V Ljubljani – Slovenia
  • Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) – Germany,
  • Istituto Ortopedico Rizzoli (IOR) – Italy
  • Servicio Madrileño De Salud (SERMAS) – Spain.
  • Uppsala Universitet (UU) – Sweden
  • Universitaetsmedizin Goettingen (UMG) – Germany
  • Beacon: For Rare Diseases (BEACON) – United Kingdom
  • The University Of Sheffield (USFD) – United Kingdom
  • University Of Hull (UHULL) – United Kingdom




The Value Added Medicines Group, a sector group of Medicines for Europe, joins the initiative as a member of the REMEDI4ALL consortium. Medicines for Europe represents the generic, biosimilar and value added medicines industries across Europe. Its member companies play a key role in creating sustainable European healthcare systems by continuing to provide high quality, effective generic medicines, whilst also innovating to create Value Added Medicines, including repurposed medicines, by tackling patients’ needs that remain unmet to this day and delivering additional improvements to the healthcare community as a whole.


Contact & interviews:


Jake Fairnie

Teamit Research

Gisela Pairó


Medicines for Europe

Medicines for Europe represents the generic, biosimilar and value-added medicines industries across Europe. Its vision is to provide sustainable access to high quality medicines, based on 5 important pillars: patients, quality, value, sustainability and partnership. Its members directly employ 190,000 people at over 400 manufacturing and 126 R&D sites in Europe and invest up to 17% of their turnover in R&D investment. Medicines for Europe member companies across Europe are both increasing access to medicines and driving improved health outcomes. They play a key role in creating sustainable European healthcare systems by continuing to provide high quality, effective generic medicines, whilst also innovating to create new biosimilar medicines and bringing to market value added medicines, which deliver better health outcomes, greater efficiency and/or improved safety in the hospital setting for patients. For more information please follow us at and on Twitter @medicinesforEU.